结核分枝杆菌Ag85复合物相关疫苗研究进展

目前全球TB疫情呈上升趋势，而惟一使用的结核病疫苗--BCG的保护效力大不如前，因此新型结核病疫苗的开发迫在眉睫。利用Ag85复合物在Mtb感染中具有明显保护性效应为基础而研制的疫苗受到广泛关注。笔者对Ag85复合物相关亚单位疫苗、重组BCG和基因疫苗研究取得的成果进行综述，结果表明少数Ag85复合物相关疫苗的保护作用超过BCG，某些新疫苗作为初种疫苗给予新生儿、儿童和青少年接种是安全、有效的；作为增强剂给予成人接种，可以提高机体免疫力；某些疫苗与化疗药物联合可以提高机体的免疫力，提高化疗效果，但能否取代BCG尚需大规模临床实验证实。

The research progression of tuberculosis vaccine on antigen85 complex

Nowadays,the prevalence and incidence of tuberculosis are on the rise in the whole world.However,the maximum protection of the only used tuberculosis vaccine-Bacilli Calmette-Guérin is limited.Therefore,it is very urgent to research and develop a new effective vaccine.Ag85 cantigen 85 complex has received a great attention in the field of new vaccine against tuberculosis because it can enhance experimental animals’immunity.This article introduced some achievements about Ag85 complex vaccines.The results showed that researchers have demonstrated that the protection of a few vaccines exceed that of traditional BCG. As a priming vaccine,it is safety and effective for newborns, children and youngsters. As a booster regimen to adults,it can enhance the anti-tuberculosis ability. Moreover, the vaccine combined with chemotherapy can improve the immunity and curative effect.But it needs more clinical trical evidence to demonstrate wether if it could replace traditional BCG.